ストックスクリーナーアプリを入手
20.09
3.55%
-0.74
Rigel Pharmaceuticals (RIGL) 最新ニュース
Rigel Pharmaceuticals (NASDAQ:RIGL) Share Price Passes Above 200-Day Moving AverageShould You Sell? - MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Short Interest Up 22.7% in January - MarketBeat
Thrombocytopenia Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, NDA Approval, Incidence, Therapies, and Companies by DelveInsight - The Globe and Mail
KFDA approves 91 medical products, including rare drug TavalisseCHOSUNBIZ - 조선비즈
Rigel Pharmaceuticals CFO Dean Schorno sells $80,614 in stock - MSN
(RIGL) Technical Pivots with Risk Controls - Stock Traders Daily
Dean L. Schorno Sells 2,036 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Stock - MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) CEO Sells $103,595.84 in Stock - MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) EVP David A. Santos Sells 2,125 Shares - MarketBeat
Rigel Pharmaceuticals executive Raymond Furey sells $59,652 in stock - MSN
Rigel Pharmaceuticals exec sells shares for $83,836 By Investing.com - Investing.com Nigeria
Rigel Pharmaceuticals exec sells shares for $83,836 - MSN
Rigel Pharmaceuticals executive Raymond Furey sells $59,652 in stock By Investing.com - Investing.com South Africa
Rigel Pharmaceuticals CEO Raul Rodriguez sells shares worth $200,075 By Investing.com - Investing.com South Africa
Rigel Pharmaceuticals CFO Dean Schorno sells $80,614 in stock By Investing.com - Investing.com South Africa
Rigel Pharmaceuticals CEO Raul Rodriguez sells shares worth $200,075 - MSN
CEO, President Rodriguez Raul R sold $200,075 worth of shares (9,352 units at $21.39), decreasing direct ownership by 4% to 239,454 units (SEC Form 4) - Quantisnow
EVP, GC, CCO & Corp Sec Furey Raymond J. sold $59,653 worth of shares (2,787 units at $21.40), decreasing direct ownership by 7% to 38,830 units (SEC Form 4) - Quantisnow
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Held Back By Insufficient Growth Even After Shares Climb 38% - Simply Wall St
EVP, Chief Commercial Officer Santos David A sold $83,836 worth of shares (3,921 units at $21.38), decreasing direct ownership by 7% to 51,704 units (SEC Form 4) - Quantisnow
BlackRock, Inc. Expands Stake in Rigel Pharmaceuticals Inc - GuruFocus.com
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Short Interest Down 43.4% in January - MarketBeat
Does Rigel (RIGL) Have the Potential to Rally 40.88% as Wall Street Analysts Expect? - MSN
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives $36.20 Average Target Price from Analysts - MarketBeat
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives $36.20 Consensus PT from Brokerages - Defense World
When (RIGL) Moves Investors should Listen - Stock Traders Daily
JPMorgan Chase & Co. Purchases 8,140 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Investor Network: Rigel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Rigel Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017 - Marketscreener.com
Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis - MarketBeat
Rigel Pharmaceuticals' SWOT analysis: diverse portfolio fuels growth, stock faces headwinds - Investing.com Australia
Rigel's fostamatinib enters Phase 1 trial for sickle cell treatment - MSN
Rigel enrols first subject in Phase I sickle cell disease therapy trial - Clinical Trials Arena
Cantor Fitzgerald Estimates RIGL FY2025 Earnings - Defense World
Rigel Pharmaceuticals' (RIGL) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease - Marketscreener.com
Rigel's fostamatinib enters Phase 1 trial for sickle cell treatment By Investing.com - Investing.com Australia
Rigel Pharmaceuticals enrolls first patient in Phase 1 study of fostamatinib - TipRanks
Equities Analysts Offer Predictions for RIGL FY2025 Earnings - MarketBeat
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):